July 13, 2005

Educational Program on Schizophrenia

This press release announces an educational program on reducing relapse for those suffering from schizophrenia. It is a free broadcast, but requires registration.

CME Outfitters, LLC, announces an upcoming live and interactive CE activity titled "Reducing Relapse: Case-Based Strategies for Achieving Successful Long-Term Outcomes in Patients with Schizophrenia." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, August 10, 2005, from 12:00 p.m.-1:00 p.m. ET, the activity will focus on providing case- and evidence-based educational information regarding the neurochemical basis of relapse in schizophrenia and offering novel strategies for reducing and preventing relapse.

Rockville, MD (PRWEB) July 12, 2005 -- CME Outfitters, LLC, nationally accredited provider of multidisciplinary medical education programming and related healthcare communications services, is pleased to announce an upcoming live and interactive CE activity titled "Reducing Relapse: Case-Based Strategies for Achieving Successful Long-Term Outcomes in Patients with Schizophrenia." Offered as a live satellite broadcast, webcast, and telephone audioconference premiering Wednesday, August 10, 2005, from 12:00 p.m.–1:00 p.m. ET, the activity will focus on providing case- and evidence-based educational information regarding the neurochemical basis of relapse in schizophrenia and offering novel strategies for reducing and preventing relapse. The recorded satellite broadcast will re-air from 3:00 p.m.–4:00 p.m. ET. This CE activity will be available as an archived webcast, podcast, and telephone audioconference shortly after the live broadcast, and available as a videotape or multimedia CD-ROM in September.

Participation in this activity is free, as is obtaining a CE certificate; however, registration is required. Three forms of registration are accepted:
Fax: View the activity details page at http://www.psychCME.net/cmea.asp?ID=119, print and complete the activity details form, and fax to 240.243.1033
Online: Visit the psychCME TV page at http://www.psychCME.net
Phone: Call 877.CME.PROS (877.263.7767)

Statement of Need:
Schizophrenia is a severe, debilitating mental illness characterized by a progressive decline in a patient’s functioning and relationship with the outside world. Although some patients recover, the risk for relapse after a schizophrenic episode remains elevated throughout the patient’s lifetime. Moreover, the risk for chronicity increases with every relapse. Therefore, one of the main goals of treatment is more effective reduction of relapse and recurrence. Studies show that atypical antipsychotics have advantages in preventing relapse of schizophrenia compared with the conventional antipsychotics in first episode patients, and even among previously stable, nonremitted patients. Many of these patients achieve symptom remission with significant improvements in multiple symptom domains and patient-rated health status after switching to atypical antipsychotics with assured compliance. Several neurotransmitter systems have been implicated in the neurobiology of schizophrenia, including dopamine, glutamate, serotonin, and norepinephrine. This case-based psychCME TV activity will explore the neurobiology of relapse in schizophrenia, define parameters that contribute to relapse, and offer novel interventions to reduce and prevent relapse and improve long-term functional outcomes.

psychCME Chair and Moderator:
Prakash S. Masand, MD
Consulting Professor of Psychiatry
Duke University Medical Center
Durham, NC

Faculty:
John M. Kane, MD
Chairman, Department of Psychiatry
The Zucker Hillside Hospital
Professor of Psychiatry, Neurology, and Neuroscience
Albert Einstein College of Medicine
Glen Oaks, NY

Robert R. Conley, MD
Chief, Treatment Research
Maryland Psychiatric Research Center
Professor of Psychiatry and Pharmacy Science
University of Maryland School of Medicine
Baltimore, MD

Learning Objectives:
At the end of this CE activity, participants should be able to:
- Identify the neurochemical basis of relapse in schizophrenia
- Describe the long-term clinical implications of preventing relapse
- Discuss novel pharmacologic strategies in preventing relapse in patients with schizophrenia

Target Audience:
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, and other healthcare professionals with an interest in mental health.

Commercial Support:
CME Outfitters, LLC, gratefully acknowledges an educational grant from Janssen Pharmaceutica in support of this CE activity.

Credit Information:
psychCME offers credit for the widest variety of clinicians compared to other broadcast CE series. This psychCME activity offers SIX types of CE credit:
1. Physicians (ACCME/AMA PRA Category 1)
2. Nurses (ANCC)
3. Pharmacists (ACPE)
4. Psychologists (APA)
5. Social Workers (NASW)
6. Certified Case Managers (CCMC)
For complete activity details and CE credit information, visit the psychCME TV page at http://www.psychcme.net

About CME Outfitters:
CME Outfitters is a full service healthcare communications agency providing continuing education content development, production, marketing, accreditation, and project management services to the healthcare industry. Among its many collaborative ventures, CME Outfitters enjoys an exclusive role in producing, certifying, and supporting the popular psychCME series of educational activities originally developed at Duke University Medical Center. For more information on CME Outfitters, including a complete calendar of its free award-winning educational activities, please visit http://www.cmeoutfitters.com, or call 877.CME.PROS (877.263.7767).

CME Outfitters' weekly e-newsletter, psychCME EXTRA, is a convenient way to stay informed of all CME Outfitters news and information. To subscribe, visit http://www.cmeoutfitters.com and click on "Register for Updates."

Contact: Christopher Perez
CME Outfitters, LLC
240.243.1303 direct
240.243.1033 fax

This press release was found on eMedia Wire.


Comments

If schizophrenia is a severe, debilitating mental illness characterized by a progressive decline in a patient’s functioning and relationship with the outside world, then how can you recover from it?

As a victim of a so called "schizophrenia" for the past 21 years, my experiences have led me to believe that the medical profession does not know what schizophrenia is, they do not know how to diagnose it and they don't know how to treat it. Considering that the so called phenomenon of schizophrenia has been around for over a century isn't it about time the medical profession came up with a unequivocal biochemical theory of schizophrenia. I believe they can't because the so called phenomenon of schizophrenia doesn't exist as a single nosological entity. I believe there must be millions of people worldwide who have been mis-diagnosed with a serious deteriorating condition of the brain and treated accordingly with toxic medication when infact their prognosis has been one of recovery. I know this as a fact because I have been one of them.

Isn't about time the medical profession got their act together once and for all before they ruin anyone else's lives with this ridiculous psedo science

Posted by: david sloggett at August 27, 2005 03:06 AM

Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required
Close